Navigation Links
WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR

SHANGHAI, China, July 2 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it has appointed Mr. Bob Zhu as Vice President of Human Resources.

(Logo: )

Prior to joining WuXi PharmaTech, Mr. Zhu worked as Head of Asia Human Resources with Electronic Arts (EA), a NASDAQ-listed American developer, marketer, publisher, and distributor of computer and video games. For the past three years, Mr. Zhu led the effort to design, implement and optimize various HR programs and processes at EA. With his help, EA successfully established its online game business and built a strong management team in Asia. Before Electronic Arts, Bob took senior HR positions in several multi- national companies. He was Regional HR Director of Tektronix, Asia Pacific Region, Senior HR Consultant of Capital One, Richmond, Virginia, U.S. and HR Director for Capital One China Operation.

Mr. Zhu will report directly to Mr. Edward Hu, Chief Operating Officer of WuXi PharmaTech.

"We are very delighted to welcome Mr. Zhu to this key position. HR strategy is an integral part of our growth strategy since people are the most valuable assets and the source of innovation at WuXi. With Bob's impressive achievements in human resources and leadership experiences from working at knowledge-based and publicly traded companies, I am confident that we will better manage our global human capital and ultimately strengthen WuXi's value- creation proposition by translating people value into financial metrics," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.

Mr. Zhu graduated from Fudan University with a BA in Law.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: .

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002


SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
2. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China
3. WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
4. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
5. WuXi PharmaTech Announces First Quarter 2008 Results
6. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
7. WuXi PharmaTech Schedules First Quarter 2008 Earnings Release on Tuesday, May 27, 2008
8. WuXi PharmaTech (NYSE: WX) Honored Among the BCG 50 Local Dynamos
9. Quest PharmaTech Receives Support from National Research Councils Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer
10. WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering
11. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
Post Your Comments:
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
Breaking Biology Technology:
(Date:11/19/2015)... 2015  Although some 350 companies are actively involved ... few companies, according to Kalorama Information. These include Roche Diagnostics, ... market share of the 6.1 billion-dollar molecular testing market, ... for Molecular Diagnostic s .    ... controlled by one company and only a handful of ...
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces ... joined its Board of Directors. --> ... after recently retiring from the partnership at TPG Capital, ... companies with over $140 Billion in revenue.  He founded ... across all the TPG companies, from 1997 to 2013.  ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
Breaking Biology News(10 mins):